4e-3 Evaluating Assessment and Medication Treatment of ADHD in Children with Down Syndrome
Project Description:
Evaluating Assessment and Medication Treatment of ADHD in Children with Down Syndrome
A new assessment study of ADHD in children with Down syndrome led by Dr. Angkustsiri is underway, after some delays in start-up due to COVID-19 restrictions. Children with Down syndrome have a greater prevalence of ADHD than typically developing children. However, rates of stimulant medication treatment are disproportionately low in children with DS+ADHD, even though stimulants are the most efficacious ADHD treatment and are recommended for use in children with ID and co-occurring ADHD. This research tests the safety and effectiveness of stimulant treatment in children with DS+ADHD and develops cardiac monitoring protocols that can be used by health providers. The clinical trial will be conducted in partnership with Pharmacy, Pulmonology, Cardiology, and local Down syndrome groups a. This innovative project addresses unrecognized attention challenges in children with Down syndrome.
Core Function(s):
Performing Research or Evaluation
Area of Emphasis
Health-Related Activities, Quality of Life, Other - Leadership
Target Audience:
Students/Trainees (long or intermediate trainees), Community Trainees / Short term trainees, Professionals and Para-Professionals, Family Members/Caregivers, Adults with Disabilities, Children/Adolescents with Disabilities/SHCN, Legislators/Policy Makers, General Public
Unserved or Under-served Populations:
Other
Primary Target Audience Geographic Descriptor:
State, National, International
COVID-19 Related Data:
N/A
